Incannex Healthcare (IXHL) Fundamentals 2026 — Revenue Analysis | SniperIQ
Incannex Healthcare (IXHL) is a AU-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Incannex Healthcare (IXHL) has a market capitalization of approximately
Incannex Healthcare's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Incannex Healthcare runs a net profit margin of -74973.0%, a gross margin of -192.7%, and an operating margin of -52287.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Incannex Healthcare reported revenue of $86,000 for fiscal year 2025, with net income of -$47M and earnings per share (EPS) of -40.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Incannex Healthcare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Incannex Healthcare carries a debt-to-equity ratio of 0.00x and a current ratio of 41.56x, with a market beta of 2.79. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Incannex Healthcare (IXHL) the key facts are: market cap
Get Incannex Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.